Importantly, any simulated past performance of the Finexia Crypto Collective is not a guarantee or reliable guide to the future performance of the product. Cryptocurrencies are extremely risky and there is no guarantee of a financial return on your investment. You may LOSE ALL or PART OF your investment. You should carefully consider your goals, risk comfort levels and seek professional financial advice before investing in the Finexia Crypto Collective. You should also obtain a copy of the PDS and TMD and consider them before making any decision to invest in the Finexia Crypto Collective.
04
Days
.
06
Hours
.
34
Minutes
.
35
Seconds
You missed out!
Dragonfly Biosciences IPO. Investment Window Open Now!
For an offer of 50,000,000 Shares at an issue price of $0.20 per Share to raise $10,000,000 (Offer).
Learn more about the IPO and Dragonfly by clicking the link below. You can register for the prospectus by following the link.
$2,000 Minimum Investment
There is a minimum investment of $2,000 which will purchase 10,000 shares in the company.
Dragonfly Biosciences is a premium retailer of health and wellness products. Through its extensive research and development, Dragonfly Biosciences controls the process from seed to sale, with the aim of producing the highest and most consistent product quality. Dragonfly Biosciences aims to expand its business and product range in line with legislative changes in sweeping across the globe. As demand grows for health supplements, Dragonfly Biosciences seeks to be the go-to-producer and supplier for both businesses and consumers. With the recent legislative changes in Australia, Dragonfly Biosciences has launched its product range here and listing on the ASX. Here is your chance to invest in an industry leader and take advantage of the global growth in the health and wellness arena.
Indicative Timetable
Lodgement of original Prospectus with the ASIC | 7 September 2021 |
Lodgement of this replacement prospectus with ASIC | 30 November 2021 |
Opening Date | 1 December 2021 |
Closing Date | 14 December 2021 |
Issue of Shares under the Offer |
15 December 2021 |
Despatch of holding statements |
15 December 2021 |
Expected date for quotation on ASX |
24 December 2021 |
As set out in further detail in Section 5 of the Prospectus, the Company has recently acquired a UK entity Dragonfly Biosciences Limited (UK Company No.10842065) (Dragonfly UK). To date,Dragonfly UK’s principal activities have comprised of developing health and wellness products. The Company is committed to delivering the highest quality products by owning and operating the entire production chain from ‘seed to shelf’. The company legally extracts oil from classified plants and develops them into wellness products. Studies show that their products may help with chronic pain, arthritis, joint pain, anxiety, sleep disorders, depression to name just a few ailments.
Register Now
Learn more about the IPO and Dragonfly by clicking the link. You can register for the prospectus by following the link.
Frequently asked questions
For more than six months now, Dragonfly has been working closely with its Australian advisers to transition the company to a listed investment on the Australian Securities Exchange (ASX).
The Prospectus includes an indicative timetable for listing [Refer to: Section 2 – Key Offer Information].
You will be able to view and access your Dragonfly shareholding via the share registry’s website; www.automic.com.au
Dragonfly shares (securities) will be traded freely on the ASX once listed. Like most global share markets, shares are traded electronically on the ASX.
You will need to set up an account with a broker, however, most Australian brokers offer online trading, so you will be able to sell your shares online and be self-directed if you chose so.
The Prospectus contains a comprehensive disclosure on the company’s actual and forecast financial performance.
Australia was chosen by the Board of Dragonfly as the jurisdiction to list its securities for several reasons, namely;
1. Australia has well developed capital markets with a deep understanding of the cannabis industry.
2. The ASX is an open and accommodating market operator for listings in the cannabis sector.
3. Australia has a rigorous corporate regulatory regime with many of the same protection measures available to investors in the UK.
4. Strategically, Australia is a natural target in the Dragonfly expansion plans as the regulatory regime towards cannabis related products is viewed as ‘friendly’ and the industry is very much in its infancy there. Australia also offers a unique proximity to the most populous region in the world, Asia.
Share certificates are no longer issued in Australia, instead shareholders are issued with a holding statement, known as an Issuer Sponsored Holding Statement. This statement sets out all of your Dragonfly shareholding details including the name of the shareholder, amount of shares held and your shareholder holder number (SRN – security holder reference number). Prior to the listing day on the ASX, the Company’s share register, Automic Group (www.automic.com.au) will dispatch your Issuer Sponsored Holding Statement. You will also be able to view and access your shareholding details on their website. To do this you will need to have your SRN at hand.
To participate in the IPO (initial public offer) you will need to complete the application contained within the Prospectus or via the online portal using the link on the application form. Applications are due to open on 14 September 2021.
You can download the Prospectus now by clicking on the button to the right or at the top of the page.
In order to sell your Dragonfly shares, in most instances, you will need to establish an account with a local Australian ASX broker. Contact the team at our lead broker, Finexia Securities and they will be more than happy to assist you. www.finexia.com.au
Contact the team at our lead broker, Finexia Securities and they will be more than happy to assist you. www.finexia.com.au
Australia: Finexia Securities
[email protected] or on 1300 886 103 (+61 7 5689 4657)
UK: Dragonfly Biosciences
[email protected] or on +44 20 7111 0807
Finexia Securities Limited is the holder of AFSL No. 485760 and a subsidiary of Finexia Financial Group (ASX:FNX).
What is an initial public offering or IPO
An initial public offering, or ‘float’, is when a private company lists on a stock exchange to raise funds by selling shares to investors, including members of the public.
Companies use IPOs to raise money that can then be reinvested to help grow the business. IPOs give investors the chance to buy shares at a set price before the company begins trading on a stock exchange, such as the ASX, in the hope that those shares will rise over time.
An IPO normally includes a minimum amount of shares that it requires investors to purchase.
Details of the proposed offering are disclosed to potential purchasers in the form of a document known as a prospectus. The prospectus provides investors with information about the business, financial statements, legal matters the company is involved with, details about the directors and officers of the company and any other material information. The prospectus also contains the application form to purchase shares, although many registrations can now be completed online.